FDA Allowed Stem Cell Banking is Now Available in the U.S.
Stem Cell Banking is now allowed under the FDA and is a great option for those who want to harvest their powerful stem cells and store them safely to use later for a wide number of conditions. The Regenerative Medicine Institute at HyperCharge Health is now making available banking and use of autologous Adipose-Derived Mesenchymal Stem Cells (ADSS) for clients who want to take advantage of the potential health benefits from this breakthrough technology for both specifically targeted conditions that may affect their spine and joints, as well as systemic degenerative and inflammatory conditions. Questions and answers regarding this exciting option are explored below.
What is the potential role for systemic (I.V. infused) ADSS in neurodegenerative, inflammatory, and other conditions with generalized symptoms?
Adipose-derived mesenchymal stem cells (MSCs) possess a natural ability to home to sites of inflammation. In degenerative and inflammatory conditions, damaged cells and tissues release cytokines that attract immune cells — and MSCs are drawn to these signals. Once at the site, MSCs may exert regenerative effects through several mechanisms, including paracrine signaling (the release of growth factors, cytokines, and exosomes), mitochondrial transfer to distressed cells, and in some cases, differentiation into functional cell types. These properties make systemic ADSS a promising approach for conditions characterized by widespread inflammation or neurodegeneration.
What is the presumed mechanism(s) of any such beneficial effect?
MSCs support healing through multiple complementary mechanisms. They can:
Differentiate into various tissue-specific cells under the right conditions.
Secrete bioactive factors (exosomes, cytokines, growth factors) that regulate inflammation, support tissue repair, and stimulate local progenitor cells — this is known as the paracrine effect.
Transfer healthy mitochondria to injured or dysfunctional cells, restoring cellular energy and function.
Modulate the immune response, reducing chronic inflammation and promoting a more regenerative environment.
These combined mechanisms allow MSCs to facilitate natural healing while minimizing scar formation and chronic inflammation.
Why should people use I.V. ADSS infusion for preventive or general “immune-boosting” purposes?
Injuries and illnesses place a significant burden on the immune system. In youth, the immune response to injury is supported by a relatively high number of circulating stem cells, enabling efficient and regenerative healing. As we age, our circulating stem cell reserves decline significantly, and the immune system responds with fewer regenerative cells and more inflammatory cells. This often leads to slower healing and increased scar formation. Periodic IV infusions of autologous stem cells may help restore regenerative balance and improve the body’s resilience to stressors by replenishing the stem cell population and tempering chronic inflammation.
What is the potential role for selectively targeted injections of ADSS as alternatives to steroids or other biologics in the treatment of degenerative or injury-related MSK and/or spinal conditions, and what are the comparative advantages?
Steroid injections can provide temporary pain relief by suppressing inflammation but do not contribute to tissue repair. In fact, by masking symptoms, they may encourage continued stress on the injured area, potentially worsening the condition over time.
Targeted stem cell injections, particularly when administered in the acute phase of an injury, aim to restore tissue integrity by promoting regeneration rather than just suppressing inflammation. Earlier intervention requires less repair, making full recovery more achievable. In chronic injuries, while more extensive repair is needed, ABSS still offers a biologically active option that addresses the root cause rather than masking symptoms.
What are the comparative advantages of ADSS over PRP or BMAC in such uses as in #4 above?
ADSS offers several key advantages:
Higher cell yield: Adipose tissue contains 500–2,000 times more mesenchymal stem cells per mL than bone marrow.
Younger, less metabolically burdened cells: Adipose-derived stem cells divide less frequently in the body (adipocytes turn over every 8–10 years), meaning their telomeres are longer and they experience less replicative stress compared to bone marrow-derived stem cells.
PRP contains few, if any, true stem cells. It primarily delivers platelets and growth factors, functioning more like a biologically active irritant to stimulate healing. PRP is best viewed as a regenerative “nudge,” while ABSS is a regenerative workforce.
In short, ADSS provides a more robust, concentrated, and longer-lasting regenerative potential than PRP or BMAC.
Why should ADSS be preferred over allogeneic stem cell preparations?
Autologous stem cells are fundamentally safer than allogeneic alternatives. They:
Pose no risk of immune rejection or graft-versus-host disease.
Carry no foreign DNA, reducing the risk of unexpected immune or genetic reactions.
Eliminate the risk of transmitting infectious diseases from donor tissue.
Remain in the body longer, providing a sustained regenerative effect, whereas allogeneic cells are often cleared from circulation within 24–72 hours.
By using your own stem cells, you maximize biocompatibility and therapeutic impact while minimizing risks.
Are there any real, substantial safety concerns with competitive allogeneic products?
Yes — as noted above, allogeneic stem cell therapies carry significant safety and efficacy concerns, including:
Risk of disease transmission.
Potential immune response or rejection.
Short lifespan in circulation post-infusion.
Lack of long-term safety data in many cases.
These risks, coupled with their rapid clearance from the body, make them less appealing than autologous alternatives for long-term regenerative goals.
The Regenerative Medicine Institute at HyperCharge Health uses American Cell Technologies (ACT) services for Adipose-Derived Stem Cell banking. What sets ACT apart from the competition in terms of safety and quality?
American Cell Technologies (ACT) operates at the highest standards of safety and compliance:
GTP-compliant, ISO-certified, and FDA-registered laboratory.
All therapies are strictly autologous, eliminating the risks associated with donor cells.
Every sample undergoes comprehensive sterility testing, including mycoplasma, endotoxin, and aerobic/anaerobic cultures.
Cells are cultured at low passages only, harvested before full confluency, and grown in GMP-grade, xeno-free media — ensuring purity and potency.
Each cell preparation is tailored to the individual sample, using a proprietary method designed to maintain the highest level of cell quality and regenerative potential.
This commitment to precision, safety, and individualized care is what sets ACT and The Regenerative Medicine Institute at HyperCharge Health apart in the field of regenerative medicine.